Nuvalent Touts 'Positive' Data From Zidesamtinib Trial For Pretreated Patients With Advanced Form Of Lung Cancer

Why did the S&P 500 surge amid Middle East ceasefire? How is the Iran-Israel truce impacting oil prices? Why did Novo Nordisk end its Hims partnership? What caused Tesla’s Robotaxi service regulatory scrutiny? How are tariff policies affecting US inflation? Why is the Fed delaying interest rate cuts? How did FedEx's latest earnings impact its stock?

Nuvalent Touts 'Positive' Data From Zidesamtinib Trial For Pretreated Patients With Advanced Form Of Lung Cancer

benzinga.com/news/health-care/25/06/46078688/nuvalent-touts-positive-data-from-zidesamtinib-trial-for-pretreated-patients-with-advanced-form-

Nuvalent, Inc. (NASDAQ:NUVL) on Tuesday announced in a press release pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) from the global ARROS-1 Phase 1/2…

This story appeared on benzinga.com, 2025-06-24 16:32:45.